James Legg
Chief Scientific Officer Cytospire Therapeutics Ltd
Dr. James Legg Ph.D is the Chief Scientific Officer at Cytospire Therapeutics. James has over 25 years experience in biologics drug discovery in the Biotech and Pharma industry. James was previously SVP Research and Early Development at Mestag Therapeutics and Crescendo Biologics. Prior to this, James started his career at Cambridge Antibody Technology before roles in AstraZeneca and MedImmune.
James holds a first class degree in Applied Biology from Bath University, a Ph.D in Molecular Cell Biology from Imperial College, London and undertook PostDoctoral research at Imperial Cancer Research Fund (Now CRUK) in London.
Seminars
Thursday 10th December 2026
Developing Novel Gamma Delta T Cell Engager Therapies; CYT X300 a Pan Gamma Delta T Cell Engager Targeting EGFR Positive Solid Tumours
9:00 am
- Cytospire is developing next generation T-cell engagers targeting γδ T-cells
- Our engagers are designed to enhance and direct key effector cells of the innate and adaptive immune system, providing a safer alternative to CD3 based engagers
- In the presentation I will describe preclinical data supporting development of CYT X300, a first-in-class pan-gamma delta T-cell engager targeting EGFR
